(888) 552-6760 SCHEDULE AN APPOINTMENT

Edward Wenge Wang,

Medical Oncologist

Biography photo
Location
Duarte Comprehensive Cancer Center
1500 East Duarte Road
Duarte, CA 91010
Specialties
Hematologic Oncology
Medical Oncology
Education
Medical school:
Board Certifications
  • 2016, American Society of Clinical Oncology Board certified

  • 2016, American Society of Hematology Board eligible

  • 2013, American Board of Internal Medicine certified

Degrees
  • 1988, B.M., Medicine, Habin Medical University, Harbin, Heilongjiang, China

  • 1991, M.S., Immunology, Harbin Medical University, Harbin, Heilongjiang, China

  • 1994, Ph.D., Tumor Immunology, Harbin Medical University, Heilongjiang, China

Fellowship
  • 2013-2016, Fellow, Hematology/Oncology, Penn State Hershey Medical Center, Hershey, Pennsylvania

Residency
  • 2011-2013, Resident, Categorical Internal Medicine, Banner University Medical Center, University Medical Center, Phoenix, Arizona

Internship
  • 2010-2011, Intern, Categorical Internal Medicine, Montefiore Mount Vernon Hospital, Mount Vernon, New York

Professional Experience
  • 2023-present, Chief of Gynecologic Oncology, Department of Medical Oncology and Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California

  • 2019-present, Associate Editor, Frontiers in Oncology: Cancer Molecular Targets and Therapeutics, a peer-reviewed professional journal

  • 2018-present, Editor, Cancer Biology and Therapy, a peer-reviewed professional journal

  • 2016-present, Director of Gynecologic Laboratory for Translational Research, Department of Medical Oncology and Therapeutics, Beckman Research Institute, City of Hope, Duarte, California

  • 2016-present, Assistant Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, California

  • 2017-2021, NIH/NCI: K12 Fellow, Paul Calabresi Career Development Award for Clinical Oncology

  • 2010, Director of Research Projects, Cancer Institute, Penn State Hershey Medical Center, Hershey, Pennsylvania

  • 2004-2010, Senior Research Investigator, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania

  • 2001-2004, Research Associate, Howard Hughes Medical Institute, University of Pennsylvania, Philadelphia, Pennsylvania

  • 1999-2001, Postdoctoral Research Scientist, Columbia University Vagelos College of Physicians and Surgeons, New York, New York

  • 1997-1999, International Special Medical Investigator, Japan Society for Promotion of Science, Osaka University Medical School, Osaka, Japan

  • 1994-1997, Postdoctoral Research Fellow, Department of Experimental Hematology, Beijing Medical Academy Institute of Radiology, Beijing, China

Academic Appointments
  • Section Chief of Gynecologic Oncology, Department of Medical Oncology & Therapeutics Research
  • Associate Professor, Department of Medical Oncology & Therapeutics Research
About Me

Dr. Edward Wenge Wang, M.D., Ph.D., is the section chief of gynecologic oncology and a tenured associate professor in the Department of Medical Oncology & Therapeutics Research, specializing in gynecologic oncology. He leads a cellular and molecular laboratory at the Beckman Research Institute, where his work focuses on translational research to advance cancer therapeutics.

Dr. Wang earned his M.D., a master’s in Immunology and a Ph.D. in Tumor Immunology from Harbin Medical University in China. He was an invited foreign special investigator in the Department of Biochemistry at Osaka University Medical School, supported by the Japan Society for the Promotion of Science. He later moved to Columbia University as a postdoctoral research scientist, followed by a position as a Research Associate with the Howard Hughes Medical Institute. He was subsequently promoted to Senior Research Investigator at the University of Pennsylvania School of Medicine.

Dr. Wang briefly served as Director of Projects at the Hershey Cancer Institute at Penn State University before completing his internal medicine internship at Montefiore Mount Vernon Hospital and residency at Banner University Medical Center. He completed his Hematology-Oncology fellowship at Penn State Hershey Medical College.

Dr. Wang is dedicated to providing exceptional patient care by combining his extensive medical knowledge and experience. He delivers personalized, evidence-based and leading-edge treatments for gynecologic cancers, guiding patients through complex treatment journeys with precision and compassion.

His research focuses on developing innovative cancer therapeutics, including immunotherapy and targeted treatments for gynecologic cancers, as well as investigating the mechanisms of tumorigenesis, disease progression and drug resistance in cancer cells.

Dr. Wang has received many intramural and extramural grants, including the Markel/Friedman Accelerator Fund for Ovarian Cancer Research, a donation from a Chicago-based anonymous foundation, the NIH K12 Career Development Award as a trainee, an NIH/NCI R21 grant for ovarian cancer-targeted therapy, the Margaret E. Early Trust Award and the Institutional Drug Development Program Award of City of Hope® for the development of an oncolytic virus designed to selectively kill cancer cells without harming normal cells. He was recently honored with the Excellence Award from Beckman Research Institute City of Hope. Dr. Wang's research is also supported by community and individual donations. He has several inventions currently undergoing the patent process and advancing toward clinical translation.

Patient ratings
Star ratings and comments are only available for medical, radiation and gynecologic oncologists. Gynecologic surgical offerings are not included at this time due to a different survey tool required to evaluate these services. CTCA uses a validated Press Ganey® survey, which captures patient experience feedback for the primary oncology services of chemotherapy and radiation therapy at our comprehensive care and research centers. Following industry best practice, star ratings and comments are only published for physicians with a minimum of 30 completed patient surveys.